UBS Group
OLMA icon

UBS Group’s Olema Pharmaceuticals OLMA Stock Holding History

UBS Group’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.74M Buy
385,061
+91,501
+31% +$2.04M ﹤0.01% 3926
2025
Q4 		$7.34M Sell
293,560
-897,094
-75% -$16M ﹤0.01% 3627
2025
Q3 		$11.7M Sell
1,190,654
-221,445
-16% -$1.33M ﹤0.01% 3124
2025
Q2 		$6.02M Buy
1,412,099
+260,952
+23% +$1.16M ﹤0.01% 3682
2025
Q1 		$4.33M Buy
1,151,147
+590,641
+105% +$2.97M ﹤0.01% 3931
2024
Q4 		$3.27M Buy
560,506
+482,959
+623% +$4.82M ﹤0.01% 4241
2024
Q3 		$926K Sell
77,547
-81,078
-51% -$1.04M ﹤0.01% 4721
2024
Q2 		$1.72M Sell
158,625
-14,536
-8% -$158K ﹤0.01% 3921
2024
Q1 		$1.96M Buy
173,161
+120,663
+230% +$1.56M ﹤0.01% 3983
2023
Q4 		$737K Buy
52,498
+38,495
+275% +$517K ﹤0.01% 4762
2023
Q3 		$173K Buy
14,003
+12,493
+827% +$127K ﹤0.01% 5457
2023
Q2 		$13.6K Buy
1,510
+1,154
+324% +$6.97K ﹤0.01% 7036
2023
Q1 		$1.24K Sell
356
-3,732
-91% -$15.2K ﹤0.01% 8775
2022
Q4 		$10K Buy
4,088
+1,657
+68% +$4.83K ﹤0.01% 8584
2022
Q3 		$7K Buy
+2,431
New +$10.3K ﹤0.01% 8891
2022
Q2 		– Sell
-26
Closed – – 10738
2022
Q1 		$0 Sell
26
-104
-80% -$573 ﹤0.01% 10707
2021
Q4 		$1K Buy
+130
New +$2.69K ﹤0.01% 10008
2021
Q2 		– Sell
-636
Closed -$21K – 9679
2021
Q1 		$21K Sell
636
-52,617
-99% -$2.25M ﹤0.01% 7340
2020
Q4 		$2.56M Buy
+53,253
New +$2.5M ﹤0.01% 3153

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

UBS Group's OLMA Position: Q1 2026 in Review

UBS Group increased its Olema Pharmaceuticals (OLMA) stake by 31% in Q1 2026, buying an estimated $2.04M and bringing the position to 385,061 shares worth $5.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

UBS Group first reported a position in OLMA in Q4 2020 and has held it in 19 quarters since. The position peaked at $11.7M in Q3 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • UBS Group held 385,061 shares of Olema Pharmaceuticals worth $5.74M as of Q1 2026.
  • UBS Group bought 91,501 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.04M.
  • Olema Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3926 holding.
  • UBS Group first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
  • UBS Group's Olema Pharmaceuticals position peaked at $11.7M in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.